2022 World Conference on Lung Cancer (ePosters)-EP03.01-010. Clinicopathological Characteristics of Non-Small Cell Lung Cancer patients in the United Arab Emirates and Correlation with Their Outcomes

EP03.01-010. Clinicopathological Characteristics of Non-Small Cell Lung Cancer patients in the United Arab Emirates and Correlation with Their Outcomes

Back to course

Pdf Summary

This study aimed to determine the clinicopathological characteristics of patients with Non-Small Cell Lung Cancer (NSCLC) in the United Arab Emirates (UAE) and to evaluate their outcomes. The study included a total of 280 NSCLC patients treated at Tawam Hospital between January 2016 and December 2020.<br /><br />The majority of the patients were males (72.1%) and of Arab ethnic origin (66.4%). Almost half of the patients had never smoked (48.2%). The most common pathology was non-squamous carcinoma (78.2%), and the majority of patients were diagnosed with stage 4 disease (75.7%).<br /><br />The study also investigated molecular features of the tumors. EGFR mutations were detected in 34% of the tested patients, while ALK rearrangements were positive in 15% of the tested patients. ROS-1 rearrangement was detected in only 2.5% of the tested patients. PD-L1 expression was tested in 198 patients, with 70% testing positive and 57.5% having PD-L1 expression of 50% or more.<br /><br />The median overall survival for stage 4 patients was 34 months. Women had a better overall survival compared to men (44 months vs. 27 months). Patients with non-squamous pathology had a longer overall survival than those with squamous pathology (40 months vs. 17 months). EGFR mutated NSCLC patients had a median overall survival of 42 months compared to 22 months for EGFR wild NSCLC. PD-L1 positive NSCLC patients also had a better outcome than the PD-L1 negative group (30 months vs. 21 months).<br /><br />Overall, the study found that NSCLC patients in the UAE often present with advanced stage and non-squamous pathology. The incidence of EGFR and ALK genetic alterations was higher compared to previous literature. Additionally, better survival outcomes were observed in women, patients with non-squamous pathology, EGFR-mutated NSCLC, and PD-L1 positive patients. These findings are consistent with previous studies.

Asset Subtitle

Fathi Azribi

Meta Tag

Speaker Fathi Azribi

Topic Epidemiology

Keywords

Non-Small Cell Lung Cancer

NSCLC

clinicopathological characteristics

United Arab Emirates

Tawam Hospital

EGFR mutations

ALK rearrangements

ROS-1 rearrangement

PD-L1 expression

overall survival